Can a simple blood test predict sarcoma recurrence?

NCT ID NCT04925089

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test for tumor DNA (ctDNA) and detailed scans can help predict how well chemotherapy works in people with a rare soft tissue cancer called leiomyosarcoma. About 40 participants will give blood samples and have scans before, during, and after treatment. The goal is to find better ways to spot early signs of cancer returning, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55901, United States

    Contact

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-••••

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Phone: •••-•••-••••